Molly Jenkins
Molly Jenkins is a senior director of Public Affairs at PhRMA, where she leads communications on the 340B hospital markup program. Before joining PhRMA, she led issue advocacy and reputation campaigns at Purple Strategies. She also worked on Capitol Hill in serval different capacities, including leading communications for Rep. Greg Walden and as press secretary for the Energy and Commerce Committee. Molly has an M.A. in Health Communication and Media Relations from Johns Hopkins University and a B.A. in journalism from Texas Christian University.
As football season kicks off, hospitals keep scoring on 340B
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
The Wall Street Journal raises new alarms about 340B
Washington Post Editorial Board says 340B has become “corporate welfare”
Congress should look under the hood of 340B, hospitals don't want them to
340B hospital markup scheme is costing states, taxpayers billions
Questions mount over 340B program and increased cost to everyone
Big, tax-exempt hospitals are charging cancer patients, employers massive medicine markups
340B’s billion-dollar boom: Oversight lags as spending soars
New study: 340B rebate model pilot won’t hurt cash flow for providers
One thing the Senate can agree on: It’s time to fix 340B
The Administration approves manufacturers’ 340B rebate pilot plans
340B abuses are fueling higher Medicare costs, new BRG report shows
ICYMI: The Wall Street Journal calls 340B reform a “good idea to cut drug costs”
340B hospitals use scare tactics to evade accountability
CBO: 340B program costs taxpayers, no evidence patients benefit
New study unmasks how big-city hospitals exploit 340B by posing as rural providers
Study: 340B hospitals drive up patient drug costs
Curbing 340B abuse and rising costs with the rebate model
The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid
New report finds rampant abuse of the 340B program
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
When hospitals have free rein to mark up drug prices, who pays the price?
New report finds more abuse of 340B program by hospitals and drug middlemen
A closer look at how health care consolidation drives up patient costs, creates barriers to care
Congress Keeps PBMs in the Hot Seat
FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs
ICYMI: The powerful companies driving local drugstores out of business
ICYMI: Hidden markups at mail-order pharmacies increase costs for employers
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
Ongoing federal probes shed light on PBM and insurer practices
WTAS: The consequences of consolidation and vertical integration
Molly Jenkins